Emerging human papillomavirus vaccines (Q56967486)

ORCID Public Data File 2021

Europe PubMed Central

title

Emerging human papillomavirus vaccines (English)

0 references

1 reference

1 reference

author name string

Barbara Ma

1

0 references

Bharat Maraj

2

0 references

Nam Phuong Tran

3

0 references

Jayne Knoff

4

0 references

Alexander Chen

5

0 references

Ronald D Alvarez

6

0 references

Chien-Fu Hung

7

0 references

T-C Wu

Expert Opinion on Emerging Drugs

8

0 references

language of work or name

English

0 references

publication date

December 2012

0 references

published in

0 references

volume

17

0 references

issue

4

0 references

page(s)

469-92

0 references

cites work

Molecular epidemiology of human papillomavirus

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Papillomaviruses and cancer: from basic studies to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Beyond cervical cancer: burden of other HPV-related cancers among men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Molecular biology of human papillomavirus infection and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Clinician's guide to human papillomavirus immunology: knowns and unknowns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Molecular mechanisms of human papillomavirus-induced carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Human papillomaviruses and the interferon response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Interferon for the treatment of genital warts: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Interferons in human papillomavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Currently approved prophylactic HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Perspectives for preventive and therapeutic HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

The role of HPV in head and neck cancer and review of the HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Reducing HPV-associated cancer globally.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Papillomavirus prophylactic vaccines: established successes, new approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Current Status of Human Papillomavirus Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Measuring serum antibody to human papillomavirus following infection or vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunobiology of HPV and HPV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Development of an HPV vaccine for a broad spectrum of high-risk types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Therapeutic HPV DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Efficient secretion of a modified E7 protein from human papilloma virus type-16 by Lactococcus lactis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Lm-LLO-Based Immunotherapies and HPV-Associated Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Carrageenan as an adjuvant to enhance peptide-based vaccine potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Activity of HspE7, a novel immunotherapy, in patients with anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

HPV & HPV vaccination: issues in developing countries.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Anti-human papillomavirus therapeutics: facts & future

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

An evidence-based review of medical and surgical treatments of genital warts.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Imiquimod: modes of action

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Imiquimod applied topically: a novel immune response modifier and new class of drug

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3786409

Carcinogenicity of human papillomaviruses

2 November 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.744393

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

21 January 2018

1 reference

12 December 2020

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

1 reference

12 December 2020

Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia

1 reference

12 December 2020

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

1 reference

12 December 2020

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

12 December 2020

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

1 reference

12 December 2020

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

12 December 2020

Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice

1 reference

12 December 2020

Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer

1 reference

12 December 2020

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 reference

12 December 2020

Fewer shots proposed to increase uptake of HPV vaccine

1 reference

12 December 2020

Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7

1 reference

12 December 2020

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

1 reference

12 December 2020

Assessing the HPV vaccine: researchers confront complex interplay of factors

1 reference

12 December 2020

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

1 reference

12 December 2020